Knut Engels
189 works · 9,761 citations · h-index 37
Top works
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers
- Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial
- A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study
- Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer
- Distinct Angiogenic patterns are associated with high-gradein situ ductal carcinomas of the breast
- Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
- Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial
- BRAF mutations in colorectal carcinoma suggest two entities of microsatellite‐unstable tumors
- Nuclear export is essential for the tumor‐promoting activity of survivin
- Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker
- Relationship of elevated tumour thymidine phosphorylase in node-positive breast carcinomas to the effects of adjuvant CMF
- T cell marker metagene predicts a favourable prognosis in estrogen receptor negative and Her2 positive breast cancers.
- Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial
- Human AP endonuclease 1 (HAP1) protein expression in breast cancer correlates with lymph node status and angiogenesis
- Angiogenesis as a biologic and prognostic indicator in human breast carcinoma
- Reversal of bone marrow angiogenesis in chronic myeloid leukemia following imatinib mesylate (STI571) therapy
- NO Signaling Confers Cytoprotectivity through the Survivin Network in Ovarian Carcinomas